Summit Therapeutics (SMMT) Earns Daily Media Sentiment Score of 0.23

Media coverage about Summit Therapeutics (NASDAQ:SMMT) has been trending somewhat positive on Thursday, Accern Sentiment reports. Accern scores the sentiment of press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Summit Therapeutics earned a media sentiment score of 0.23 on Accern’s scale. Accern also gave media stories about the company an impact score of 44.5880577005553 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Shares of Summit Therapeutics (NASDAQ SMMT) traded down $0.10 during trading hours on Thursday, reaching $12.00. The company’s stock had a trading volume of 50,200 shares, compared to its average volume of 42,473. The firm has a market capitalization of $176.55 and a price-to-earnings ratio of -120.00. Summit Therapeutics has a 12 month low of $8.80 and a 12 month high of $16.86.

Summit Therapeutics (NASDAQ:SMMT) last announced its quarterly earnings results on Wednesday, December 6th. The company reported ($0.20) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.73) by $0.53. Summit Therapeutics had a negative return on equity of 10.90% and a negative net margin of 0.95%. research analysts forecast that Summit Therapeutics will post -0.59 EPS for the current fiscal year.

Several equities analysts recently weighed in on SMMT shares. Canaccord Genuity reiterated a “buy” rating on shares of Summit Therapeutics in a research report on Monday, October 16th. Oppenheimer reiterated a “buy” rating and set a $24.00 target price on shares of Summit Therapeutics in a research report on Monday, October 16th. HC Wainwright set a $16.00 target price on Summit Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, December 27th. SunTrust Banks started coverage on Summit Therapeutics in a research note on Thursday, January 4th. They set a “buy” rating and a $24.00 price target for the company. Finally, Zacks Investment Research upgraded Summit Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, January 5th. One investment analyst has rated the stock with a sell rating, four have assigned a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $21.20.

TRADEMARK VIOLATION WARNING: This report was posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://www.tickerreport.com/banking-finance/3144484/summit-therapeutics-smmt-earns-daily-media-sentiment-score-of-0-23.html.

About Summit Therapeutics

Summit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).

Insider Buying and Selling by Quarter for Summit Therapeutics (NASDAQ:SMMT)

Receive News & Ratings for Summit Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.